Wedbush reaffirmed their buy rating on shares of Millendo Therapeutics (NASDAQ:MLND) in a research report released on Thursday, AnalystRatings.com reports. They currently have a $24.00 price target on the stock. Wedbush also issued estimates for Millendo Therapeutics’ Q4 2019 earnings at ($1.01) EPS, FY2019 earnings at ($3.45) EPS and FY2020 earnings at ($3.52) EPS.
MLND has been the subject of several other research reports. Citigroup initiated coverage on Millendo Therapeutics in a report on Monday, July 15th. They set an outperform rating and a $26.00 price objective for the company. Oppenheimer cut their price objective on Millendo Therapeutics from $26.00 to $25.00 and set an outperform rating for the company in a report on Tuesday, August 13th. ValuEngine raised Millendo Therapeutics from a hold rating to a buy rating in a report on Thursday, August 1st. Zacks Investment Research raised Millendo Therapeutics from a sell rating to a hold rating in a report on Tuesday, July 16th. Finally, CIBC initiated coverage on Millendo Therapeutics in a report on Tuesday, July 16th. They set an outperform rating and a $26.00 price objective for the company. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock currently has an average rating of Buy and an average target price of $22.97.
Shares of NASDAQ MLND opened at $6.98 on Thursday. Millendo Therapeutics has a 12 month low of $6.63 and a 12 month high of $17.34. The company has a current ratio of 5.90, a quick ratio of 7.83 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $91.47 million, a price-to-earnings ratio of -0.40 and a beta of 2.64. The business has a 50-day moving average of $10.18 and a 200-day moving average of $13.06.
Millendo Therapeutics (NASDAQ:MLND) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.74) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.81) by $0.07. On average, analysts predict that Millendo Therapeutics will post -3.22 earnings per share for the current year.
A number of large investors have recently added to or reduced their stakes in MLND. BlackRock Inc. lifted its position in Millendo Therapeutics by 1,738.4% in the 2nd quarter. BlackRock Inc. now owns 468,342 shares of the company’s stock worth $5,414,000 after buying an additional 442,866 shares during the last quarter. Vanguard Group Inc. lifted its position in Millendo Therapeutics by 62.2% in the 2nd quarter. Vanguard Group Inc. now owns 331,285 shares of the company’s stock worth $3,829,000 after buying an additional 126,994 shares during the last quarter. International Biotechnology Trust PLC lifted its position in Millendo Therapeutics by 187.5% in the 2nd quarter. International Biotechnology Trust PLC now owns 177,825 shares of the company’s stock worth $2,056,000 after buying an additional 115,965 shares during the last quarter. Renaissance Technologies LLC lifted its position in Millendo Therapeutics by 100.3% in the 2nd quarter. Renaissance Technologies LLC now owns 208,864 shares of the company’s stock worth $2,414,000 after buying an additional 104,567 shares during the last quarter. Finally, AWM Investment Company Inc. lifted its position in Millendo Therapeutics by 288.1% in the 2nd quarter. AWM Investment Company Inc. now owns 77,629 shares of the company’s stock worth $897,000 after buying an additional 57,629 shares during the last quarter. Institutional investors own 44.03% of the company’s stock.
Millendo Therapeutics Company Profile
Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.
Recommended Story: Why do companies issue convertible shares?
Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.